July 25th 2024
According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.
July 4th 2024
Low risk of elevated IOP with lampalizumab for geographic atrophy over 1 year
July 2nd 2024Repeated 0.1-ml intravireal injections of lampalizumab, antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D, seem to be associated with a low risk of elevated IOP
Read More
Pegcetacoplan injection preserves visual function at 36 weeks in patients with geographic atrophy
June 11th 2024Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.
Read More
According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.
Read More
Caroline Baumal, Chief Medical Officer at Apellis, spoke with Ophthalmology Times on the GALE extension study of pegcetacoplan for geographic atrophy, and shared insights on her career transition, emphasizing the significance of mentorship and a passion for one’s work at this year's American Academy of Ophthalmology meeting in San Francisco.
Read More
Clinical characteristics and progression of Geographic Atrophy in a Japanese population
November 7th 2023This retrospective, multicenter, observational study examined Japanese patients with GA to determine the clinical characteristics and GA progression rate associated with AMD in an Asian population.
Read More